Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,648 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Stereotactic Ablative Radiotherapy Versus Low Dose Rate Brachytherapy or External Beam Radiotherapy: Propensity Score Matched Analyses of Canadian Data.
Loblaw A, Pickles T, Crook J, Martin AG, Vigneault E, Souhami L, Cury F, Morris J, Catton C, Lukka H, Cheung P, Sethukavalan P, Warner A, Yang Y, Rodrigues G; Genitourinary Radiation Oncologists of Canada (GUROC). Loblaw A, et al. Among authors: cheung p. Clin Oncol (R Coll Radiol). 2017 Mar;29(3):161-170. doi: 10.1016/j.clon.2016.10.001. Epub 2016 Oct 22. Clin Oncol (R Coll Radiol). 2017. PMID: 27780694
Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
Shahid N, Loblaw A, Chung HT, Cheung P, Szumacher E, Danjoux C, Sankreacha R, Zhang L, Deabreu A, Mamedov A, Morton G. Shahid N, et al. Among authors: cheung p. Clin Oncol (R Coll Radiol). 2017 Jul;29(7):412-420. doi: 10.1016/j.clon.2017.01.042. Epub 2017 Feb 9. Clin Oncol (R Coll Radiol). 2017. PMID: 28190638 Clinical Trial.
Prostate-specific Antigen Bounce After Stereotactic Body Radiotherapy for Prostate Cancer: A Pooled Analysis of Four Prospective Trials.
Roy S, Loblaw A, Cheung P, Chu W, Chung HT, Vesprini D, Ong A, Chowdhury A, Panjwani D, Pang G, Korol R, Davidson M, Ravi A, McCurdy B, Helou J, Zhang L, Mamedov A, Deabreu A, Quon HC. Roy S, et al. Among authors: cheung p. Clin Oncol (R Coll Radiol). 2019 Sep;31(9):621-629. doi: 10.1016/j.clon.2019.05.001. Epub 2019 May 21. Clin Oncol (R Coll Radiol). 2019. PMID: 31126725
Absolute percentage of biopsied tissue positive for Gleason pattern 4 disease (APP4) appears predictive of disease control after high dose rate brachytherapy and external beam radiotherapy in intermediate risk prostate cancer.
Martell K, Mendez LC, Chung H, Tseng CL, Zhang L, Alayed Y, Liu S, Vesprini D, Chu W, Paudel M, Cheung P, Szumacher E, Ravi A, Loblaw A, Morton G. Martell K, et al. Among authors: cheung p. Radiother Oncol. 2019 Jun;135:170-177. doi: 10.1016/j.radonc.2019.03.007. Epub 2019 Mar 27. Radiother Oncol. 2019. PMID: 31015164
Phase I/II study of a five-fraction hypofractionated accelerated radiotherapy treatment for low-risk localised prostate cancer: early results of pHART3.
Tang CI, Loblaw DA, Cheung P, Holden L, Morton G, Basran PS, Tirona R, Cardoso M, Pang G, Gardner S, Cesta A. Tang CI, et al. Among authors: cheung p. Clin Oncol (R Coll Radiol). 2008 Dec;20(10):729-37. doi: 10.1016/j.clon.2008.08.006. Epub 2008 Oct 5. Clin Oncol (R Coll Radiol). 2008. PMID: 18838256 Clinical Trial.
1,648 results